Home › Cervical Cancer › Georgia
Cervical Cancer clinical trials in Georgia
15 studies for Cervical Cancer are looking for participants at sites in Georgia.
Cities in Georgia
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- Emory University, Atlanta
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT06465069Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer
- Piedmont Healthcare, Atlanta
RecruitingObservational study
Ages 18 and older · Women · Updated Sep 29, 2026 · NCT05051722Ocular Assessments in Patients Treated With Tivdak® in Recurrent or Metastatic Cervical Cancer
- Grady Health System Correll Pavilion, Atlanta
- Grady Memorial Hospital Investigational Drug Service, Atlanta
- Emory University Hospital Midtown, Atlanta
- and 4 more
RecruitingPhase 4
Ages 18 and older · Women · Updated Sep 25, 2026 · NCT06952660A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
- Winship Cancer Institute of Emory University ( Site 5005), Atlanta
- Nancy N. & J.C. Lewis Cancer and Research Pavillion - Research Department ( Site 6005), Savannah
RecruitingPhase 3
Ages 18 and older · Women · Updated Sep 25, 2026 · NCT07216703Pembrolizumab and Lenvatinib in Advanced Cervical Cancer
- Georgia Cancer Center at Augusta University, Augusta
RecruitingPhase 2
Ages 18 and older · Women · Updated Sep 10, 2026 · NCT04865887Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
- Georgia Cancer Center at Augusta University, Augusta
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 10, 2026 · NCT06293898A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
- Emory University, Atlanta
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 4, 2026 · NCT06400472Cryocompression With or Without Cilostazol for the Prevention of Paclitaxel-induced Neuropathy in Patients With Gynecological Cancers
- Emory University Hospital Midtown, Atlanta
- Emory University Hospital/Winship Cancer Institute, Atlanta
- Emory Saint Joseph's Hospital, Atlanta
RecruitingPhase 2
Ages 18 and older · Women · Updated Aug 27, 2026 · NCT06492070Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S04)
- Emory University Hospital/Winship Cancer Institute, Atlanta
RecruitingHealthy volunteers welcome
Ages 25 and older · Women · Updated Jul 31, 2026 · NCT07281430A Trial of Robotic Versus Open Hysterectomy Surgery in Cervix Cancer
- Georgian Cancer Center at Augusta University, Augusta
Recruiting
Ages 18 and older · Women · Updated Jul 30, 2026 · NCT04831580First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
- Winship Cancer Institute, Emory University, Atlanta
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jul 7, 2026 · NCT05768139cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
- North Georgia Health System, Gainesville
RecruitingObservational studyHealthy volunteers welcome
Ages 40 and older · All sexes · Updated Jan 20, 2026 · NCT05366881A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
- Research Site 114, Atlanta
- Research Site 139, Atlanta
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 21, 2025 · NCT05914116SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Atlanta
- Massive Bio SYNERGY-AI site, Savannah
RecruitingObservational study
All ages · All sexes · Updated Oct 28, 2025 · NCT03452774A Beta-only IL-2 ImmunoTherapY Study
- Emory - Winship Cancer Institute, Atlanta
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jul 9, 2025 · NCT05086692From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.